GAITHERSBURG, Md., Jan. 10 /PRNewswire/ -- Panacea Pharmaceuticals,
Inc. announced the appointment of Pamela Harris, MD, as Vice President
Medical and Clinical Affairs. Dr. Harris will lead the design and conduct
of clinical trials for the Company's therapeutic and diagnostic products
for cancer and diseases of the central nervous system, and provide
information to physicians and other health care providers on these
diseases, and their diagnosis and treatment.
Dr. Harris has broad experience with the design and conduct of early-
and late-stage clinical trials involving products intended for a range of
diseases and conditions, including cancer and HIV infection. Most recently,
Dr. Harris was the Chief Medical Officer at Callisto Pharmaceuticals, where
she was responsible for the development of two antineoplastic drugs. Prior
to this position, she served as a Team Leader and Senior Medical Director
at Pfizer, Director of Clinical Research at Wyeth Pharmaceuticals, and
Director of Clinical Research at U.S. Bioscience. In addition, Dr. Harris
has served as a consultant to Nabi Pharmaceuticals and Hoffman La-Roche.
Dr. Harris received her M.D. degree from Ohio State University, and
completed a residency in internal medicine at the Washington Hospital
Center in Washington DC. She did research fellowship work at the Sloan
Kettering Institute for Cancer Research, Georgetown University Medical
Center, and Jackson Memorial Hospital in Miami, FL. Dr. Harris also
completed a hematology and oncology clinical fellowship at the George
Washington University Hospital in Washington DC. Dr. Harris is board
certified in internal medicine and medical oncology, and has authored more
than 25 peer-reviewed publications.
"Panacea will soon initiate clinical trials for its first therapeutics
to treat cancer and stroke. We have introduced our first cancer diagnostic
product to predict sensitivity to imatinib (Gleevec(R)) in patients with
Chronic Myelogenous Leukemia, and will soon introduce our second diagnostic
test to aid in the screening for prostate cancer. Dr. Harris will expedite
the development of all of these products," noted Stephen Keith, MD, MSPH,
President and Chief Operating Officer. "Dr. Harris brings a wealth of
experience in clinical trials and medical affairs, having worked at both
large pharmaceutical companies and smaller biotech companies. She is a
welcome addition to our team."
About Panacea's Oncology Platform
Panacea is pursuing the development of antibodies directed against
Human aspartyl (asparaginyl) Beta-hydroxylase (HAAH) as novel agents for
the treatment of cancer with liver cancer as its first intended indication.
The Company is exploring both naked anti-HAAH antibodies as well as HAAH
antibodies conjugated to chemotherapeutic agents. Panacea is also pursuing
the development of diagnostic products based on HAAH gene expression and
anti- HAAH antibodies. A test to determine responsiveness to a current
therapy of choice in patients with chronic myelogenous leukemia utilizing
HAAH gene expression is available through Panacea Laboratories. A
proprietary blood- based assay has shown high sensitivity and specificity
in the detection of a range of cancers, thus facilitating the diagnosis and
therapeutic management of disease. Initial targets for the blood-based
diagnostic products include prostate and liver cancers.
About Panacea Pharmaceuticals, Inc.
Panacea Pharmaceuticals, Inc. is a privately-held biopharmaceutical
company focused on the development and commercialization of therapeutics
and diagnostics for diseases with substantial, unmet clinical needs. The
Company's product development strategy is based on novel therapeutic agents
and approaches for cancer treatment, as well as acute and chronic
neurodegenerative conditions, such as hypoxia-induced neurological insult,
Parkinson's Disease, and Alzheimer's Disease. Panacea has an extensive
patent portfolio covering its neurodegenerative and oncology technologies.
More information about the Company is available at
http://www.PanaceaPharma.com.
Except for historical information presented in this press release,
matters discussed herein may constitute "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995.
Forward- looking statements are based on the opinions and estimates of
management only as of the date of this release and are subject to certain
risks and uncertainties that could cause actual results to differ
materially from any future results, performance, or achievements expressed
or implied by such statements. Factors that might cause such a difference
include, but are not limited to, uncertainties related to our access to
capital, the progress, costs, and results of any clinical trials undertaken
by us, progress of our research and development projects, and uncertainties
related to whether our product candidates would ultimately achieve
commercial success. We do not undertake any obligation to update publicly
any forward-looking statement, whether as a result of new information,
future events, or otherwise unless required by law.
Contact:
Panacea Pharmaceuticals, Inc.
Stephen N. Keith, MD, MSPH
President & COO
Phone 240-243-8000; FAX 240-465-0450
skeith@panaceapharma.com
SOURCE Panacea Pharmaceuticals, Inc.
 back to top
Related links:
http://www.panaceapharma.com/
CONTACT:
Stephen N. Keith, MD, MSPH, President & COO
of Panacea Pharmaceuticals, Inc., +1-240-243-8000, Fax:
+1-240-465-0450, skeith@panaceapharma.com
|
